OptimizeRx/$OPRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Ticker

$OPRX
Sector
Primary listing

Employees

129

OptimizeRx Metrics

BasicAdvanced
$328M
-
-$0.54
1.33
-

What the Analysts think about OptimizeRx

Analyst ratings (Buy, Hold, Sell) for OptimizeRx stock.

Bulls say / Bears say

Q2 2025 revenue jumped 55% year-over-year to $29.2 million, driven by strong demand for OptimizeRx's digital point-of-care messaging solutions. (GlobeNewswire)
Management increased full-year 2025 revenue guidance to $104 million–$108 million and raised adjusted EBITDA guidance to $14.5 million–$17.5 million, signaling confidence in ongoing growth. (GlobeNewswire)
OptimizeRx paid down $4.5 million in principal on its term loan during Q2, highlighting strong free cash flow and a commitment to reducing leverage. (GlobeNewswire)
59% of total revenue in Q2 2025 came from the top 20 pharmaceutical manufacturer clients, highlighting the risk of customer concentration in a competitive digital health market. (GlobeNewswire)
Net revenue retention fell to 121% over the twelve months ended June 30, 2025, compared to 124% in the previous year, signaling possible challenges in upselling or customer retention. (GlobeNewswire)
GAAP net income of $1.5 million on Q2 revenue of $29.2 million reflects a slim net margin of about 5%, suggesting constrained scalability of profitability. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2025.

OptimizeRx Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

OptimizeRx Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OPRX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy OptimizeRx stock | $OPRX Share Price | Lightyear